Watch for stockholder vote on charter amendment to increase authorized shares, which is required for warrant exercisability. Also monitor Q4 2026 updated Phase 1/2 combination data for MICVO with KEYTRUDA, which could affect sentiment. The company's cash runway into H1 2028 depends on warrant exercise; failure to obtain stockholder approval or negative OS data could trigger further dilution or financing needs.
Price Chart
Executive Summary
Pyxis Oncology closed a ~$110M public offering on October 1, 2026, selling 36M shares and pre-funded warrants for 1.9M shares, plus milestone-linked common warrants for 49.3M shares at $3.50/strike. The warrants are contingent on stockholder approval and disclosure of overall survival data for lead candidate MICVO in HNSCC, expected H1 2027. The company warns existing cash plus offering proceeds fund operations into H1 2028 but may be insufficient for the planned Phase 3 trial without warrant exercise.
Key Financial Metrics
Key Facts
- Closed underwritten public offering on October 1, 2026, generating ~$110M in upfront gross proceeds.
- Offering consisted of 36,047,919 common shares at $2.90/share and pre-funded warrants for 1,883,121 shares at $2.899 each.
- Common warrants to purchase 49,310,352 shares at $3.50/strike (21% premium to offering price) are contingent on stockholder approval and overall survival data disclosure for MICVO.
- If all milestone-linked warrants are exercised for cash, total gross proceeds would be ~$282.6M.
- Net proceeds to fund lead ADC program MICVO through planned Phase 3 trial in 2L+ R/M HNSCC and for working capital.
- Company states existing cash plus offering proceeds fund operations into H1 2028, but warns without warrant exercise, proceeds are insufficient to fully fund the planned Phase 3 Headliner trial.
- Updated Phase 1/2 combination data of MICVO with Merck's KEYTRUDA expected in Q4 2026.
- Participants include OrbiMed, GordonMD Global Investments, BVF Partners, Coastlands Capital, and RTW Investments.
Financial Impact
Upfront gross proceeds of ~$110M; potential total of ~$282.6M if all warrants exercised. Dilution from 36M shares plus up to 49.3M additional shares via warrants.
Risk Factors
- Significant dilution from 36M shares issued plus up to 49.3M additional shares via warrants.
- Warrant exercise contingent on stockholder approval and positive OS data; failure could reduce potential proceeds.
- Company warns existing cash plus offering proceeds may be insufficient for planned Phase 3 trial without warrant exercise.
- Clinical risk: MICVO Phase 1 data may not support Phase 3; negative OS data could impair warrant value and stock price.
- Stockholder approval for charter amendment is not guaranteed.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3373740 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Press Release | $1.66 | awaiting T+5 | — | $1.84 (+10.84%) |
Oct 21, 2026 6d ago | DEF 14A | $1.71 | awaiting T+5 | — | $1.84 (−7.60%) |
Oct 9, 2026 18d ago | SC 13G/A | $2.03 $1.68 | ▼ −17.24% | ▼ −15.27% | $1.84 (−9.36%) |
Oct 2, 2026 25d ago | SC 13G/A | $2.14 $2.03 | ▼ −5.14% | ▼ −6.30% | $1.84 (−14.02%) |
Oct 2, 2026 25d ago | Press Release | $2.14 $2.03 | ▲ +5.14% | ▲ +6.30% | $1.84 (+14.02%) |
Oct 1, 2026 26d ago | 8-K | $2.14 $2.03 | ▲ +5.14% | ▲ +6.30% | $1.84 (+14.02%) |
Oct 1, 2026 26d ago | 424B5 | $2.19 $1.99 | ▲ +9.13% | ▲ +10.43% | $1.84 (+15.98%) |
Sep 30, 2026 28d ago | Press Release | $2.33 $2.01 | ▲ +13.73% | ▲ +15.65% | $1.84 (+21.03%) |
Sep 9, 2026 6w ago | 8-K | $3.38 $3.34 | ▼ −1.18% | ▼ −0.09% | $1.84 (−45.56%) |
Sep 8, 2026 7w ago | 8-K | $3.89 $3.33 | ▼ −14.40% | ▼ −13.28% | $1.84 (−52.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers